The Impact of Locoregional Treatment on Survival of Patients With Primary Metastatic Breast Cancer

Abstract

The aim of the study was to investigate the impact of primary tumor locoregional treatment (surgery or/and radiotherapy) on overall survival in patients with primary metastatic breast cancer (PMBC). Materials and Methods: This retrospective study included 295 wo men aged from 23 to 76 years with PMBC. Among the 295 patients, the effect of locoregional treatment of primary tumor on survival outcomes was evaluated in 177 women with distant metastases at diagnosis of breast cancer. 35 patient received breast surgery (group 1), 95 patients with PMBC — radiotherapy (group 2) and 47 patients — combination of breast surgery and radiation (group 3). The remaining 118 patients didn’t receive surgery or/and radiotherapy (group 4). All patients received systemic cytotoxic chemotherapy. Results: The groups of patients with PMBC did not differ significantly by age, menstrual function, ER status, Her2 receptor status, site of metastasis and number of metastatic lesions. 2- and 5-year overall survival in patients of group 1 was 54 and 32%, group 2 — 47 and 8%, group 3 — 73 and 18%, whereas in patients from group 4 — 26 and 9%, respectively. The median survival of patients who underwent surgery was 36 months, patients with PMBC who received radiotherapy — 24 months, patients who obtained combination of breast surgery and radiation — 30 months vs 18 months in patients who did not undergo primary tumor locoregional treatment. Conclusions: The results of this study showed a favourable effect of locoregional treatment in patients with PMBC.

Computer Tomography Radiomics-Based Nomogram in the Survival Prediction for Brain Metastases From Non-Small Cell Lung Cancer Underwent Whole Brain Radiotherapy

“…Due to this heterogeneity, prognostic features and treatment options for patients with BM should be carefully investigated on an individual basis. Although there is still controversy for the palliative treatment for BM patients with poor prognosis, multidisciplinary palliative therapy must be administered to increase the OS rates of patients with good prognosis ( 28 ).…”

Systemic chemotherapeutic treatment of patients with breast cancer brain metastases

“…Main evidences of SAT effectiveness for BCBM treatment were obtained in patients with extracranial metastases, but the extracranial spread is known as more frequent cause of death than intracranial progression. [4]. The studies investigating the SAT efficacy in patients with BCBM demonstrate the response rate ranged from 4% to 38% and in some cases above 65% [12].…”

“…The prognosis determination is of importance for decision making in BCBM treatment. In patients with a poor prognosis, the appropriateness of anticancer therapy is debatable, and in patients with a good prognosis, multimodal palliative care can increase survival rates [4]. Moreover, disease prognostic scales can be used for improving the applicability, objectivity and validity of the results of clinical trials studying the treatment efficacy of BCBM.…”

Effects of surgeon volume and hospital volume on clinical outcomes of breast cancer patients

“…Over the past decades, approach to breast cancer treatment has been changing dynamically, but with surgical intervention remaining the leading one. The purpose of surgical treatment is to achieve control of the disease, prevent loco-regional recurrence and increase the survival rate of patients even in patients with primary metastatic breast cancer (2). A modern treatment strategy for breast cancer patients is becoming highly complex, requiring a multidisciplinary approach.…”